Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Electrocore (ECOR – Research Report), Disc Medicine (IRON – Research Report) and Allakos (ALLK – Research Report).
Electrocore (ECOR)
Maxim Group analyst Anthony Vendetti maintained a Buy rating on Electrocore yesterday and set a price target of $15.00. The company’s shares closed last Thursday at $6.85.
According to TipRanks.com, Vendetti ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Electrocore with a $15.00 average price target, which is a 104.4% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.
See today’s best-performing stocks on TipRanks >>
Disc Medicine (IRON)
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on Disc Medicine today and set a price target of $48.00. The company’s shares closed last Thursday at $30.77, close to its 52-week low of $25.60.
According to TipRanks.com, Katkhuda is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $53.63 average price target, representing an 86.7% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $70.00 price target.
Allakos (ALLK)
In a report released today, Sam Slutsky from LifeSci Capital maintained a Hold rating on Allakos. The company’s shares closed last Thursday at $1.29, close to its 52-week low of $0.98.
According to TipRanks.com, Slutsky is a 5-star analyst with an average return of
Allakos has an analyst consensus of Hold, with a price target consensus of $3.25.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ECOR:
- electroCore reports Q1 EPS (53c), consensus (62c)
- electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
- electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024
- electroCore announces results of Truvaga Plus consumer study
- Truvaga™ Plus Demonstrates Health Benefits in Latest Consumer Study, Paving the Way for Market Expansion
